Skip to main content
Figure 1 | Cardiovascular Diabetology

Figure 1

From: The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

Figure 1

Characteristics of control mice and those fed sitagliptin. There were no significant differences in body weight (A), food intake (B), blood glucose (C), or blood lipids (D) between the two groups, except for a significantly increased HDL cholesterol level in mice in the sitagliptin group. Data are mean ± SD, n = 12 per group.

Back to article page